Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

At the @MassBio Dinner on board #diversity this week w leaders from @jpmorgan, @NASA, #FrequencyTx @PolarisVC, Kaleido BioScience & Dimock Community Health Center. An illuminating and important conversation that we are pleased to be part of as we shape the future of our industry

We are pleased to announce that Abraham Scaria will be in #London Nov. 27th speaking at the #Ophthalmic Drugs Conference 2018 on #GeneDelivery and #GeneEditing in the #Retina https://t.co/RtaK7ZeN9G

See us on Twitter